Piper Jaffray Starts Celyad SA (CYAD) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
UPDATE: UBS Starts Celyad SA (CYAD) at Buy
July 14, 2015 8:22 AM EDT(Updated - July 14, 2015 8:43 AM EDT)
UBS initiates coverage on Celyad SA (NASDAQ: CYAD) with a Buy rating and a price target of $82.00.
Analyst Andrew Peters commented, "We are initiating coverage on Celyad SA with a Buy rating and $82 price target following an extensive analysis of the phase-3 C-Cure program in heart failure as well as the NK-based CAR-T technology currently in phase-1 trials. We believe initial proofof-concept data from... More
